Literature DB >> 25366364

Comment on "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].

Thomas C Booth1, Adam D Waldman, Sarah Jefferies, Rolf Jäger.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25366364     DOI： 10.1007/s11060-014-1649-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


× No keyword cloud information.
  13 in total

1.  Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma.

Authors:  Marc C Chamberlain; Michael J Glantz; Lisa Chalmers; Alixis Van Horn; Andrew E Sloan
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

2.  Differentiation of true progression from pseudoprogression in glioblastoma treated with radiation therapy and concomitant temozolomide: comparison study of standard and high-b-value diffusion-weighted imaging.

Authors:  Hee Ho Chu; Seung Hong Choi; Inseon Ryoo; Soo Chin Kim; Jeong A Yeom; Hwaseon Shin; Seung Chai Jung; A Leum Lee; Tae Jin Yoon; Tae Min Kim; Se-Hoon Lee; Chul-Kee Park; Ji-Hoon Kim; Chul-Ho Sohn; Sung-Hye Park; Il Han Kim
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

3.  Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status.

Authors:  D-S Kong; S T Kim; E-H Kim; D H Lim; W S Kim; Y-L Suh; J-I Lee; K Park; J H Kim; D-H Nam
Journal:  AJNR Am J Neuroradiol       Date:  2011-01-20       Impact factor: 3.825

Review 4.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

5.  Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma.

Authors:  Rajiv Mangla; Gurshawn Singh; Doerthe Ziegelitz; Michael T Milano; David N Korones; Jianhui Zhong; Sven E Ekholm
Journal:  Radiology       Date:  2010-06-07       Impact factor: 11.105

Review 6.  The concepts, diagnosis and management of early imaging changes after therapy for glioblastomas.

Authors:  P Sanghera; R Rampling; B Haylock; S Jefferies; C McBain; J H Rees; C Soh; I R Whittle
Journal:  Clin Oncol (R Coll Radiol)       Date:  2011-07-23       Impact factor: 4.126

7.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

8.  MRI perfusion in determining pseudoprogression in patients with glioblastoma.

Authors:  Robert J Young; Ajay Gupta; Akash D Shah; Jerome J Graber; Timothy A Chan; Zhigang Zhang; Weiji Shi; Kathryn Beal; Antonio M Omuro
Journal:  Clin Imaging       Date:  2012-06-08       Impact factor: 1.605

9.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.

Authors:  Alba A Brandes; Enrico Franceschi; Alicia Tosoni; Valeria Blatt; Annalisa Pession; Giovanni Tallini; Roberta Bertorelle; Stefania Bartolini; Fabio Calbucci; Alvaro Andreoli; Giampiero Frezza; Marco Leonardi; Federica Spagnolli; Mario Ermani
Journal:  J Clin Oncol       Date:  2008-05-01       Impact factor: 44.544

Review 10.  The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.

Authors:  Timothy Charles Ryken; Nafi Aygun; Johnathan Morris; Marin Schweizer; Rajeshwari Nair; Cassandra Spracklen; Steven N Kalkanis; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2014-04-09       Impact factor: 4.130
View more
  3 in total

Review 1.  High-Grade Glioma Treatment Response Monitoring Biomarkers: A Position Statement on the Evidence Supporting the Use of Advanced MRI Techniques in the Clinic, and the Latest Bench-to-Bedside Developments. Part 1: Perfusion and Diffusion Techniques.

Authors:  Otto M Henriksen; María Del Mar Álvarez-Torres; Patricia Figueiredo; Gilbert Hangel; Vera C Keil; Ruben E Nechifor; Frank Riemer; Kathleen M Schmainda; Esther A H Warnert; Evita C Wiegers; Thomas C Booth
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 5.738

2.  Imaging Biomarkers of Glioblastoma Treatment Response: A Systematic Review and Meta-Analysis of Recent Machine Learning Studies.

Authors:  Thomas C Booth; Mariusz Grzeda; Alysha Chelliah; Andrei Roman; Ayisha Al Busaidi; Carmen Dragos; Haris Shuaib; Aysha Luis; Ayesha Mirchandani; Burcu Alparslan; Nina Mansoor; Jose Lavrador; Francesco Vergani; Keyoumars Ashkan; Marc Modat; Sebastien Ourselin
Journal:  Front Oncol       Date:  2022-01-31       Impact factor: 6.244

Review 3.  Machine learning and glioma imaging biomarkers.

Authors:  T C Booth; M Williams; A Luis; J Cardoso; K Ashkan; H Shuaib
Journal:  Clin Radiol       Date:  2019-07-29       Impact factor: 2.350
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.